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A B S T R A C T  
Objective: This study was aimed to compare the mean lipid profile in calcific aortic stenosis patients and control group. 
Patients and Methods: Total 202 individuals, 101 cases and 101 controls visiting National Institute of Cardiovascular 
Disease and various tertiary care hospitals of Karachi from January 2012 to December 2012 were included in this study. 
Calcific AS patients having the age of ≥60 years fulfilling the inclusion criteria were selected from echocardiography 
department and OPD from NICVD. Age and gender match controls were selected from OPD. Lipid profile was done in 
DDRRL, Ojha Campus. Lipid profile estimates were carried out on HITACHI 902 analyzer using photometry technique. 
Results: Nonparametric Mann-Whitney test showed increase level of Triglyceride in calcific AS patients. 
Conclusion: Calcific AS patients showed altered lipid profile as compare to control group so dyslipidemia may be 
involved in its pathogenesis. 
Keywords: Calcific aortic stenosis, Cholesterol, Dyslipidemias, High density lipoprotein, Low density, lipoprotein, 
Triglyceride.
Author`s Contribution 
1 Conceived the topic of research, 
designed the study, data collection, 
Literature review and manuscript writing 
2 Discussion, Critical review, 3 Data 
analysis, 4 Critical Review, 5 Compiling 
results, 
Address of Correspondence 
Erum Afaq 
Email. doc_erum@yahoo.com 
Article info. 
Received: May 31, 2017 
Accepted: July 9, 2017 
 
Cite this article: Afaq E, Hassan H, Nisar MK, Afaq H, Naheed K. Comparison of Mean 
Lipid Profile in Calcific Aortic Stenosis Cases and Controls.JIMDC. 2017; 6(3):140-143 
Funding Source: Nil 
Conflict of Interest: Nil 
I n t r o d u c t i o n  
Severe calcific aortic stenosis (AS) is one of the most 
commonly encountered valvular pathologies requiring 
surgery in developed countries.1 It is postulated that an 
early lesion in AS is characterized by subendothelial 
thickening on the aortic side of the leaflet because of 
accumulation of cellular lipid infiltration and extracellular 
mineralization, accompanied by a proliferation of smooth 
muscle cells and lipid-laden foam cells resembling 
atherosclerotic plaques.2 There are similarities between 
risk factors for coronary atherosclerosis and the 
development of AS, which suggests that the 
atherosclerotic process involving aortic valve leaflets 
eventually brings about or accelerates the thickening of 
the leaflet structure, leading to significant AS.3-5 In 
patients with familial hypercholesterolemia, high 
cholesterol concentrations are associated with the 
development of AS.6,7 Many cardiovascular studies have 
proved that  there is a link between atherosclerotic risk 
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factors and the factors associated with the prevalence 
and  progression of calcific AS.8 That includes elevated 
LDL cholesterol, lipoprotein (a), hypertension, male 
gender and smoking.9  This information can leads the way 
as lipid lowering drugs may be the treatment of choice for 
prevention and delay the progression of calcific AS.10,11  
In Pakistan no such data is available. We designed this 
retrospective case-control study to evaluate the 
relationship between altered lipid profilein 
echocardiographically diagnosed patients with calcific AS, 
who referred to echocardiography department and OPD 
for further evaluation and to compare the mean values of 
lipid profile in calcific AS patients and controls. 
    P a t i e n t s  a n d  M e t h o d s  
This study was conducted in National Institute of 
Cardiovascular Disease (NICVD) and DDRRL, Ojha 
Campus DIMC, Dow University of Health Sciences 
(DUHS). Study was approved by ethical review committee 
of NICVD and DUHS. Patients were selected from 
echocardiography department and OPD from NICVD. A 
detailed history was taken and Elderly patients (age≥60 
years) having calcific AS were included in the study. For 
controls, age and gender matched persons without calcific 
AS were inducted. Patients having severe aortic 
regurgitation, history of endocarditis, rheumatoid arthritis, 
rheumatic fever or rheumatic heart disease and 
echocardiographic evidence of rheumatic valvular 
stenosis, chronic renal failure, familial 
hypercholesterolemia (total cholesterol >300 mg/dL in 
adults), cancer, prosthetic valves or patient taking lipid 
lowering drugs were excluded from the study. The 
patients were documented brased on their written consent 
on a detailed prescribed performa. Study was completed 
in 2 years after approval from Board of Advanced 
Scientific Research (BASR) and Funding Committee of 
Dow University of Health Science. Sample size was 
calculated with the help of open Epi 
(http://www.openepi.com/SampleSize/SSMean.htm) by 
taking mean total cholesterol in AS patients as 211±43 
mg/dl, mean total cholesterol in patients without aortic 
stenosis as 193±48 mg/dl,12 power of 80% and 
confidence interval of 95%. The calculated sample size 
was 202 patients, 101 in each case and control groups. 
Non-probability purposive sampling technique was used. 
Fasting blood samples were collected from both the case 
and control groups for lipid profiling. Lipid profile 
estimates were carried out on HITACHI 902 analyzer 
using photometry technique in DDRRL, Ojha Campus. 
Data was entered in Microsoft Excel and analyzed using 
SPSS version 21. Descriptive analysis was done 
according to the type of variable. Numeric data was 
analyzed by calculating mean and standard deviation 
(SD). Frequencies and percentages were calculated for 
categoric variables. As the data was nonparametric, 
median and range were taken. The nonparametric Mann-
Whitney test was used to compare the two groups. P-
value less than 0.05 was considered to be statistically 
significant. 
R e s u l t s  
A total of 202 individuals were recruited in our study. Total 
101 elderly people as calcific AS cases and 101 age and 
gender matched controls. The age and gender distribution 
among two groups is presented in table I. The mean age 
and standard deviation for the cases was 67.09±5.04 and 
the mean age and standard deviation for controls was 
66.72±3.68. There were 63 (62.4%) males and 38 
(37.6%) females in the case group and 67 (66.3%) male 
and 34 (33.7%) females were included in control group.  
Histogram and Shapiro-Wilk test were applied to check 
the normality. As the variables are violating the 
assumption of normality therefore nonparametric Mann-
Whitney test was used to compare both cases and 
controls. Triglyceride level showed significant difference 
between both the groups as mentioned in table 2. 
Table 1: Demographic profile in cases and controls 
Variables Cases 
 
Controls 
 
Age (years) Mean 67.09 66.72 
SD 5.04 3.68 
Gender Males   n (%) 63 (62.4) 67 (66.3) 
Female n 
(%) 
38 (37.6) 34 (33.7) 
 
Table 2: Descriptive statistics of lipid profile in both groups 
Lipid profile 
(mg/dl) 
Cases Controls p-Value 
Median 
(Range) 
Median 
(Range) 
Triglyceride 114 (421) 140 (356) <0.001 
Total Cholesterol 160 (177) 152 (218) 0.739 
HDL 39 (40) 40 (34.8) 0.524 
LDL 93 (119) 88 (118) 0.087 
D i s c u s s i o n  
Multiple studies have shown many similarities in the 
histopathologic features of atherosclerosis and calcific 
AS.3,13,14 There is also an overlap in the risk factors of 
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calcific AS and atherosclerosis, among them one is 
dyslipidemia. 8,15,16 In this study fasting lipid profile was 
done among calcific AS cases and controls. There was a 
difference in the mean triglyceride level in cases and 
controls with significant p-value <0.05. These findings are 
in contrast to Peltier et al 2003, who showed a higher 
level of triglyceride in AS cases.12 In our study, the cause 
of triglyceridemia may be due to the presence of coronary 
artery disease in controls.17  
Mean total cholesterol showed the insignificant difference 
in both groups. This finding is consistent with the findings 
of a study conducted by Ortlepp 2006 and in contrast to 
the study conducted by Peltier et al who found that there 
is hypercholesteremia in patients of calcific AS. 18 Models 
of atherosclerotic disease in rabbits and rats have also 
been used to determine the effects of 
hypercholesterolemia on the aortic valve morphology and 
function.19 Insignificant values in our study may be due to 
presence of comorbidities in both groups. 
HDL-cholesterol showed insignificant p-value but HDL- 
cholesterol was decreased in both the groups. The case-
control study conducted by Park et al. 2013, showed that 
decrease in HDL-cholesterol was associated with the AS 
and its progression.20 Novaro et al. 2003, showed an 
insignificant association of HDL-cholesterol with cases 
and controls. However, in his work patients had a normal 
level of HDL-cholesterol.21 In our study, insignificant p-
value for HDL-cholesterol might be due to the fact that 
both groups included female participants above sixty 
years of age and in females, HDL- Cholesterol decreases 
as age increases. 
Regarding mean LDL-cholesterol, our study showed non-
significant p-value. The study was consistent with the 
results of Novaro et al. 2003, who showed insignificant p-
value of LDL cholesterol between cases and controls. 21 
However, Moura et al 2007 showed higher level of LDL 
cholesterol in calcific AS patients. 22 In humans, a strong 
influence has been observed of the LDL cholesterol levels 
on the progression of AS, as quantified by electron beam 
tomography using a volumetric score.23 
C o n c l u s i o n  
Calcific AS is a multifactorial disease. The present study 
concluded that calcific AS patients have altered lipid 
profile as compared to control group so dyslipidemia may 
be involved in its pathogenesis. However, in some 
patients, the presence of coronary artery disease may 
have produced symptoms, predominantly angina, which 
incited investigation and hence resulted in bias towards 
finding an association between aortic stenosis and altered 
lipid profile. 
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